Drug Trial Radar · NCT06768671
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Dec 30, 2024
Primary completion
Sep 28, 2026
Study completion Sep 28, 2026
Sponsor
- Lead sponsor
- MoonLake Immunotherapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Conditions
- Hidradenitis Suppurativa
Interventions
SonelokimabDrug
Open label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) of sonelokimab in adolescentsTime frame: Week 24
- Adverse events (AEs) following treatment with sonelokimab in adolescentsTime frame: Week 24
- Discontinuation of sonelokimab treatment due to AEsTime frame: Week 24
- Clinically significant changes in clinical laboratory parametersTime frame: Week 24
- Clinically significant changes in vital signsTime frame: Week 24
- Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervalsTime frame: Week 24
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site
North Little Rock, Arkansas
Clinical Site
Stanford, California
Clinical Site
Washington D.C., District of Columbia
Clinical Site
Hollywood, Florida
Clinical Site
Miami, Florida
Clinical Site
Macon, Georgia
Clinical Site
Sandy Springs, Georgia
Clinical Site
Chicago, Illinois
Clinical Site
Columbus, Indiana
Clinical Site
Murray, Kentucky
Clinical Site
Waterford, Michigan
Clinical Site
Fargo, North Dakota
Clinical Site
Charleston, South Carolina
Clinical Site
Dallas, Texas
Clinical Site
Dallas, Texas
Clinical Site
San Antonio, Texas
Clinical Site
Norfolk, Virginia
Clinical Site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.